Hanmi Pharmaceutical Co. Ltd. has described son of sevenless homolog 1 (SOS1) inhibitors reported to be useful for the treatment of cancer.

Beyond Therapeutics Co. Ltd. has divulged menin (MEN1)/MLL interaction inhibitors reported to be useful for the treatment of cancer.

Bayer AG has identified α2C-adrenoceptor antagonists reported to be useful for the treatment of dysphagia, snoring, neurodegeneration, neuroinflammation and cardiovascular disorders.

Bristol Myers Squibb Co. has synthesized receptor-interacting serine/threonine-protein kinase 1 (RIPK1; RIP-1) inhibitors reported to be useful for the treatment of inflammatory bowel disease, psoriasis, rheumatoid arthritis, nonalcoholic or metabolic dysfunction-associated steatohepatitis (NASH/MASH), multiple sclerosis, amyotrophic lateral sclerosis, heart failure and Alzheimer’s disease.

Chengdu Chipscreen Pharmaceutical Ltd. has disclosed integrin αvβ1 and/or αvβ6 antagonists reported to be useful for the treatment of fibrosis.

Researchers from Shanghai Electric Power Hospital have presented a study investigating NSUN5-mediated m5C modification in cholangiocarcinoma.

Researchers at the Chinese Academy of Medical Sciences and Peking Union Medical College have prepared a nanobody against mpox virus.

Acetaminophen (APAP), although recognized as a safe and effective antipyretic and analgesic drug, can lead to acute liver failure if taken in excess.